Literature DB >> 19841431

Central nervous system germ cell tumors: classification, clinical features, and treatment with a historical overview.

Takamitsu Fujimaki1.   

Abstract

Central nervous system germ cell tumors are neoplasms that affect children and young adults. They are subclassified into germinoma and nongerminomatous germ cell tumors. The latter include teratoma (mature teratoma, immature teratoma, teratoma with malignant transformation), choriocarcinoma, embryonal carcinoma, yolk sac tumors, and mixtures of these entities. Germinoma with syncytiotrophoblastic giant cells is a variant of germinoma. Germinomas respond well to radiation therapy, but late sequelae due to irradiation have been reported. The results of radiation treatment alone for nongerminomatous germ cell tumor are not satisfactory. Combination radiochemotherapy has been applied, and this yields a good outcome with less toxicity for germinomas and better survival of nongerminomatous germ cell tumors. This article also discusses other issues, including the controversy regarding spinal irradiation and the treatment of recurrent disease.

Entities:  

Mesh:

Year:  2009        PMID: 19841431     DOI: 10.1177/0883073809342127

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  25 in total

1.  Primary yolk sac tumour of the prostate mimicking small round blue cell tumour.

Authors:  H Gui; R A Kolster; M B Palmer; J S Brooks; M Zhang; M A Husson
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

2.  Clinical reasoning: Multiple cranial neuropathies in a young man.

Authors:  John C Probasco; Ashley T Munchel; Justin C McArthur; Jaishri O Blakeley
Journal:  Neurology       Date:  2013-02-05       Impact factor: 9.910

3.  Freiburg neuropathology case conference: a midline mass lesion in an infant.

Authors:  C A Taschner; O Staszewski; V van Velthoven; M Müller; U Kontny; C Hader; M Prinz
Journal:  Clin Neuroradiol       Date:  2011-06       Impact factor: 3.649

4.  Pure germinomas of the central nervous system: treatment strategies and outcomes.

Authors:  Adam Schoenfeld; Daphne A Haas-Kogan; Annette Molinaro; Anu Banerjee; Theodore Nicolaides; Tarik Tihan; Andrew W Bollen; Nalin Gupta; Sabine Mueller
Journal:  J Neurooncol       Date:  2014-09-05       Impact factor: 4.130

5.  Enlarging teratoma syndrome.

Authors:  İdris Sertbaş; Mete Karatay
Journal:  Childs Nerv Syst       Date:  2018-08-29       Impact factor: 1.475

6.  A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma.

Authors:  Meser M Ali; Mohammed Pi Bhuiyan; Branislava Janic; Nadimpalli Rs Varma; Tom Mikkelsen; James R Ewing; Robert A Knight; Mark D Pagel; Ali S Arbab
Journal:  Nanomedicine (Lond)       Date:  2012-08-14       Impact factor: 5.307

Review 7.  Targeted imaging and therapy of brain cancer using theranostic nanoparticles.

Authors:  Mahaveer Swaroop Bhojani; Marcian Van Dort; Alnawaz Rehemtulla; Brian D Ross
Journal:  Mol Pharm       Date:  2010-10-27       Impact factor: 4.939

8.  Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.

Authors:  Jason Fangusaro; Shengjie Wu; Shannon MacDonald; Erin Murphy; Dennis Shaw; Ute Bartels; Soumen Khatua; Mark Souweidane; Hsiao-Ming Lu; David Morris; Ashok Panigrahy; Arzu Onar-Thomas; Maryam Fouladi; Amar Gajjar; Girish Dhall
Journal:  J Clin Oncol       Date:  2019-09-23       Impact factor: 44.544

9.  Neuropsychological functions and quality of life in survived patients with intracranial germ cell tumors after treatment.

Authors:  Shih-Yuan Liang; Tsui-Fen Yang; Yi-Wei Chen; Muh-Lii Liang; Hsin-Hung Chen; Kai-Ping Chang; Ian-Kai Shan; Ying-Sheue Chen; Tai-Tong Wong
Journal:  Neuro Oncol       Date:  2013-10-06       Impact factor: 12.300

Review 10.  The adolescent and young adult with cancer: state of the art--brain tumor.

Authors:  Sidnei Epelman
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.